PND9 COST UTILITY ANALYSIS OF LEVODOPA-CARBIDOPA VS LEVODOPA-CARBIDOPA-ENTACAPONE IN PARKINSON DISEASE IN MEXICO
✍ Scribed by F Garcia-Contreras; A Nevarez-Sida; P Constantino-Casas; E Rojas-Martínez; M García-Constantino; G Del Angel-García
- Book ID
- 119594638
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 72 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1098-3015
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patie
## Abstract We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. On